243 related articles for article (PubMed ID: 31005313)
1. Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study.
Valero A; Isla A; Rodríguez-Gascón A; Canut A; Ángeles Solinís M
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Dec; 37(10):626-633. PubMed ID: 31005313
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients.
Valero A; Isla A; Rodríguez-Gascón A; Calvo B; Canut A; Solinís MÁ
Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(6):380-386. PubMed ID: 30449456
[TBL] [Abstract][Full Text] [Related]
3. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
4. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
5. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
8. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals.
Keel RA; Kuti JL; Sahm DF; Nicolau DP
Am J Health Syst Pharm; 2011 Sep; 68(17):1619-25. PubMed ID: 21856807
[TBL] [Abstract][Full Text] [Related]
11. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
[TBL] [Abstract][Full Text] [Related]
12. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
Frei CR; Hampton SL; Burgess DS
Clin Ther; 2006 Jul; 28(7):1035-40. PubMed ID: 16990081
[TBL] [Abstract][Full Text] [Related]
13. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
Zelenitsky SA; Rubinstein E; Ariano RE; Zhanel GG;
J Antimicrob Chemother; 2013 May; 68 Suppl 1():i67-72. PubMed ID: 23587780
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
15. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
16.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa: Evaluation of Pathogen Burden and Drug-Resistance Trends in a Tertiary Care Hospital.
Saeed M; Rasheed F; Afzal RK; Hussain S; Riaz S; Ahmad A
J Coll Physicians Surg Pak; 2018 Apr; 28(4):279-283. PubMed ID: 29615167
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective.
Ibar-Bariain M; Rodríguez-Gascón A; Isla A; Solinís MÁ; Canut-Blasco A
Enferm Infecc Microbiol Clin (Engl Ed); 2021 Feb; 39(2):65-71. PubMed ID: 32636039
[TBL] [Abstract][Full Text] [Related]
20.
Valero A; Rodríguez-Gascón A; Isla A; Barrasa H; Del Barrio-Tofiño E; Oliver A; Canut A; Solinís MÁ
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
